Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has established a new anti-infective research unit at the Murdoch Children's Research Institute in Melbourne, one of the top three children’s research institutes in the world.
Securing this research space supports the company’s expanding pre-clinical programs with world-leading infectious disease researchers who are dedicating their efforts to a suite of pre-clinical studies investigating the antimicrobial activity of RECCE® compounds.
Recce’s work with Murdoch Children's has already played a pivotal role in the delivery of results surrounding ongoing pre-clinical programs, generating R327 data demonstrating strong bactericidal activity against a range of deadly pathogens.
What’s more, the planned research activities conducted in Recce’s AIR Unit will have a particular focus on advancing the company’s Bacterial Sinusitis program, Mycobacterium abscessus, and more with all intellectual property rights and results owned by the company.
Impressive resources and clinical expertise
The programs continue to be led by Dr Phil Sutton, former head of Murdoch Children's Mucosal Immunology and Recce’s vice president of translational sciences.
Sutton said: “We are thrilled by this agreement with Murdoch Children's, as it will give Recce direct access to critical pre-clinical laboratory studies.
“Access to the facilities within one of the world’s leading research institutes will also allow us to draw upon their impressive resources and clinical expertise.”
About Murdoch Children's
Murdoch Children's Research Institute is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact.
Based in Melbourne, one of the world’s most innovative cities for world-leading medical research and development, the dedicated research within Recce’s AIR Unit will streamline ongoing pre-clinical programs and explore new research development opportunities.
Recce CEO James Graham said: “With access to Murdoch Children's world-leading facilities, this agreement will further advance our pre-clinical programs.
“We are delighted to collaborate with Murdoch Children's in addressing unmet medical needs and look forward to advancing anti-infective research.”